BSc RN - Spectral Med VP Devel
| EDT Stock | CAD 0.56 0.01 1.75% |
Insider
BSc RN is VP Devel of Spectral Med
| Address | 135 The West Mall, Toronto, ON, Canada, M9C 1C2 |
| Phone | 416 626 3233 |
| Web | https://spectraldx.com |
Spectral Med Management Efficiency
The company has return on total asset (ROA) of (0.9322) % which means that it has lost $0.9322 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.7397) %, meaning that it generated substantial loss on money invested by shareholders. Spectral Med's management efficiency ratios could be used to measure how well Spectral Med manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Spectral Med's Return On Capital Employed is very stable compared to the past year. As of the 27th of November 2024, Return On Equity is likely to grow to 0.99, though Return On Tangible Assets are likely to grow to (2.97). At this time, Spectral Med's Other Current Assets are very stable compared to the past year. As of the 27th of November 2024, Debt To Assets is likely to grow to 1.60, while Total Assets are likely to drop about 5 M.Similar Executives
| Found 8 records | INSIDER Age | ||
| Samuel MD | Medicenna Therapeutics Corp | N/A | |
| MBBS MD | Medicenna Therapeutics Corp | N/A | |
| Fahar Merchant | Medicenna Therapeutics Corp | 67 | |
| Janet CA | Aptose Biosciences | N/A | |
| Dr MA | Helix BioPharma Corp | N/A | |
| Kevin Cassidy | Microbix Biosystems | N/A | |
| MBA MBA | Helix BioPharma Corp | 63 | |
| Mark Luscher | Microbix Biosystems | N/A | |
Management Performance
| Return On Equity | -9.74 | ||||
| Return On Asset | -0.93 |
Spectral Med Leadership Team
Elected by the shareholders, the Spectral Med's board of directors comprises two types of representatives: Spectral Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectral. The board's role is to monitor Spectral Med's management team and ensure that shareholders' interests are well served. Spectral Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectral Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sam Amory, Pres Inc | ||
| BSc RN, VP Devel | ||
| Blair McInnis, Chief Officer | ||
| Christopher Seto, CEO Director | ||
| John MD, Chief Officer |
Spectral Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectral Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.74 | ||||
| Return On Asset | -0.93 | ||||
| Operating Margin | (9.46) % | ||||
| Current Valuation | 163.21 M | ||||
| Shares Outstanding | 282.82 M | ||||
| Shares Owned By Insiders | 18.13 % | ||||
| Shares Owned By Institutions | 12.95 % | ||||
| Number Of Shares Shorted | 95.22 K | ||||
| Price To Earning | (16.07) X | ||||
| Price To Book | 49.87 X |
Pair Trading with Spectral Med
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectral Med position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will appreciate offsetting losses from the drop in the long position's value.Moving against Spectral Stock
| 0.89 | PYPL | PayPal Holdings CDR | PairCorr |
| 0.84 | INTC | INTEL CDR | PairCorr |
| 0.74 | TSLA | Tesla Inc CDR | PairCorr |
| 0.73 | NVDA | NVIDIA CDR | PairCorr |
| 0.65 | GOOG | Alphabet CDR | PairCorr |
The ability to find closely correlated positions to Spectral Med could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectral Med when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectral Med - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectral Med to buy it.
The correlation of Spectral Med is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectral Med moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectral Med moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectral Med can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.